Supernus Pharmaceuticals (SUPN)
(Real Time Quote from BATS)
$32.14 USD
+0.08 (0.25%)
Updated Oct 8, 2024 12:26 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
View All Zacks #1 Ranked Stocks
Supernus Pharmaceuticals (SUPN) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $39.25 | $43.00 | $36.00 | 22.43% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Supernus Pharmaceuticals comes to $39.25. The forecasts range from a low of $36.00 to a high of $43.00. The average price target represents an increase of 22.43% from the last closing price of $32.06.
Analyst Price Targets (4 )
Broker Rating
Supernus Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 2.00 | 2.00 | 2.00 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 9/11/2024 | Piper Sandler | David Amsellem | Hold | Hold |
| 5/24/2024 | Not Identified | Not Identified | Hold | Hold |
| 4/1/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 2.00 |
| ABR (Last week) | 2.00 |
| # of Recs in ABR | 4 |
| Average Target Price | $39.25 |
| LT Growth Rate | NA |
| Industry | Medical - Generic Drugs |
| Industry Rank by ABR | 40 of 252 |
| Current Quarter EPS Est: | 0.39 |
SUPN FAQs
Supernus Pharmaceuticals, Inc. (SUPN) currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Supernus Pharmaceuticals, Inc. (SUPN) is $39.25. The current on short-term price targets is based on 3 reports.
The forecasts for Supernus Pharmaceuticals, Inc. (SUPN) range from a low of $36 to a high of $43. The average price target represents a increase of $22.43 from the last closing price of $32.06.
The current UPSIDE for Supernus Pharmaceuticals, Inc. (SUPN) is 22.43%
Based on short-term price targets offered by four analysts, the average price target for Supernus Pharmaceuticals comes to $39.25. The forecasts range from a low of $36.00 to a high of $43.00. The average price target represents an increase of 22.43% from the last closing price of $32.06.